bioAffinity Technologies (bioAffinity Technologies) Effective Interest Rate on Debt % : 6.25% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. bioAffinity Technologies's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.10 Mil. bioAffinity Technologies's average total debt for the quarter that ended in Mar. 2024 was $1.54 Mil. Therefore, bioAffinity Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 6.25%.

bioAffinity Technologies Effective Interest Rate on Debt % Historical Data

The historical data trend for bioAffinity Technologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies Effective Interest Rate on Debt % Chart

bioAffinity Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

3.82

9.38

43.61

4.04

bioAffinity Technologies Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial									3.81	3.81	4.17	6.13	6.25

Competitive Comparison of bioAffinity Technologies's Effective Interest Rate on Debt %

For the Diagnostics & Research subindustry, bioAffinity Technologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioAffinity Technologies's Effective Interest Rate on Debt % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Effective Interest Rate on Debt % falls into.

bioAffinity Technologies Effective Interest Rate on Debt % Calculation

bioAffinity Technologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -0.037	/	( (0.252	+	1.578)	/ 2 )
=	-1 * -0.037	/	0.915
=	4.04 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0.252
=	0.252

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.118	+	0.46
=	1.578

bioAffinity Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * -0.096	/	( (1.578	+	1.495)	/ 2 )
=	-1 * -0.096	/	1.5365
=	6.25 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.118	+	0.46
=	1.578

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.021	+	0.474
=	1.495

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

bioAffinity Technologies (NAS:BIAF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

bioAffinity Technologies Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

bioAffinity Technologies (bioAffinity Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257

Website

https://www.bioaffinitytech.com

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.

Executives

Roby Joyce	director	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles	officer: Chief Operating Officer	22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty	officer: Chief Financial Officer	2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards	officer: Chief Financial Officer	30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight	director	6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti	director, officer: Executive Chairman	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Gary D Rubin	director, 10 percent owner	2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond	director	498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes	director, officer: President, CEO	19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust	10 percent owner	21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji	director	C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel	officer: EVP, Chief Sci. & Med. Officer	8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes	officer: Secretary, EVP, Gen. Counsel	1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter	10 percent owner	28 PARRISH POND LANE, SOUTHAMPTON NY 11968